At the present time, approved targeted therapy agents in advanced RCC include bevacizumab, a monoclonal antibody that blocks VEGF-A by preventing its binding to the VEGF receptor; tyrosine kinase inhibitors (TKIs) that mainly exert their activity by inhibiting the VEGF receptor and include sorafenib, sunitinib, pazopanib, and axitinib; inhibitors of the mTOR complex, such as temsirolimus and everolimus. This evidence concerns the gene VEGFA and renal cell carcinoma.